Image

Global Psoriatic Arthritis (PsA) Market– Industry Tren ds and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Jun 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Psoriatic Arthritis (PsA) Market, By Types (Symmetric PsA, Asymmetric PsA, Spondylitis PsA Psoriatic Arthritis Mutilans, Distal Interphalangeal Predominant PsA), Treatment (Medication, Surgery, Others), Diagnosis (X-rays, Magnetic Resonance Imaging (MRI), Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

 

Psoriatic Arthritis (PsA) Market

Market Analysis and Size

Psoriatic arthritis is a type of arthritis that affects some people who have psoriasis, a skin ailment marked by red areas and silvery scales. The majority of patients get psoriasis first and then get psoriatic arthritis later; however joint issues might start before the skin patches do. The main indications and symptoms of psoriatic arthritis include joint pain, stiffness, and edema. Psoriatic arthritis can strike any region of your body, including your fingertips and spine, and symptoms can range from moderate to severe. Psoriatic arthritis can affect either one or both sides of the body's joints.

Data Bridge Market Research analyses that the psoriatic arthritis (PsA) market was valued at USD 11.26 billion in 2021 and is expected to reach USD 23.10 billion by 2029, registering a CAGR of 9.40% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Types (Symmetric PsA, Asymmetric PsA, Spondylitis PsA Psoriatic Arthritis Mutilans, Distal Interphalangeal Predominant PsA), Treatment (Medication, Surgery, Others), Diagnosis (X-rays, Magnetic Resonance Imaging (MRI), Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Merck & Co., Inc. (U.S.),  F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Cadila Pharmaceuticals (India), Eli Lilly and Company (U.S.), LEO Pharma A/S (Denmark), Cipla Inc. (U.S.), Aurobindo Pharma (India), Lupin (India), Sumitomo Corporation (Japan)

Market Opportunities

 

  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies

Market Definition

Psoriatic arthritis (PsA) is an inflammatory condition that affects the joints and the areas where tendons and ligaments link to bone. Psoriatic arthritis doesn't have a cure. Controlling inflammation in affected joints to avoid joint pain and impairment and controlling skin involvement are the main goals of treatment. Prescription pharmaceuticals known as disease-modifying antirheumatic drugs are one of the most common treatments (DMARDs). For those with mild psoriatic arthritis, nonsteroidal anti-inflammatory drugs (NSAIDs) can help alleviate pain and inflammation. Artificial metal and plastic joints can be used to replace some of the joints that have been significantly destroyed by psoriatic arthritis.

Psoriatic Arthritis (PsA) Market Dynamics

Drivers

  • Rise in the prevalence of psoriatic arthritis (PsA)

The rising prevalence of psoriatic arthritis (PsA) is a major factor driving the psoriatic arthritis (PsA) market's growth rate. Psoriatic arthritis is a degenerative disease that is linked to psoriasis. The condition can cause irreparable joint damage if not treated properly and promptly. Although the specific cause of the disease is unknown, research reveals that genetic factors are responsible for approximately 40% of cases. 

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of psoriatic arthritis (PsA) market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness about the will expand the psoriatic arthritis (PsA) market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of psoriatic arthritis (PsA) market. Along with this, the rising geriatric population and surge in biological therapy approval will enhance the market's growth rate.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the psoriatic arthritis (PsA) market growth. The launch of breakthrough medicines in the psoriatic arthritis treatment market is driving research-driven understanding of the pathophysiology of psoriatic arthritis, stimulating innovations among market participants – thereby promoting the growth of the psoriatic arthritis treatment market. Targeted biological therapy has a good success rate in producing transient pain alleviation in patients with psoriatic arthritis, and hence continues to hold a promising position in the psoriatic arthritis treatment market.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of psoriatic arthritis (PsA) during the forecast period.

Restraints/Challenges

On the other hand, high cost of the medication will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and low awareness about psoriatic arthritis (PsA) and its associated complications will pose major challenges to the market's growth rate. Additionally, the dearth of favorable reimbursement policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This psoriatic arthritis (PsA) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the psoriatic arthritis (PsA) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The psoriatic arthritis (PsA) market also provides detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Recent Development

  • In December 2021, AbbVie announced the U.S. Food and Drug Administration (FDA) approval of RINVOQ (upadacitinib; 15 mg, once daily) for treating adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. RINVOQ is a JAK inhibitor that is being researched for use in various immune-mediated inflammatory disorders. RINVOQ showed stronger inhibitory potency for JAK-1 compared to JAK-2, JAK-3, and TYK-2 in enzymatic and cellular studies.

Global Psoriatic Arthritis (PsA) Market Scope

The psoriatic arthritis (PsA) market is segmented on the basis of types, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

  • Symmetric PsA
  • Asymmetric PsA
  • Spondylitis PsA
  • Psoriatic Arthritis Mutilans
  • Distal Interphalangeal Predominant PsA

Treatment

  • Medication
  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Disease-modifying antirheumatic drugs (DMARDs)
  • Immunosuppressant
  • Corticosteroids
  • Others
  • Surgery
  • Joint replacement surgery
  • Others
  • Others

Diagnosis

  • X-rays
  • Magnetic Resonance Imaging (MRI)
  • Others

Route of Administration

  • Oral
  • Topical
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Psoriatic Arthritis (PsA) Market Regional Analysis/Insights

The psoriatic arthritis (PsA) market is analysed and market size insights and trends are provided by country, types, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the psoriatic arthritis (PsA) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the psoriatic arthritis (PsA) market because of the growing presence of major key players and the rising number of research and development activities will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to the surging number of generic manufacturers and growing government initiatives in this region. Also, the development of healthcare infrastructure will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Psoriatic Arthritis (PsA) Market Share Analysis

The psoriatic arthritis (PsA) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to psoriatic arthritis (PsA) market.

Some of the major players operating in the psoriatic arthritis (PsA) market are:

  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Boehringer Ingelheim International GmbH. (Germany)
  • AstraZeneca (U.K.)
  • Johnson & Johnson Private Limited (U.S.)
  • Bayer AG (Germany)
  • Merck & Co., Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Bristol-Myers Squibb Company (U.S.)
  • Cadila Pharmaceuticals (India) 
  • Eli Lilly and Company (U.S.)
  • LEO Pharma A/S (Denmark)
  • Cipla Inc. (U.S.)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Sumitomo Corporation (Japan)

Research Methodology: Global Psoriatic Arthritis (PsA) Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The market value for psoriatic arthritis (PsA) market is expected USD 23.10 billion by 2029.
The Psoriatic Arthritis (PsA) Market is to grow at a CAGR of 9.40% during the forecast by 2029.
The major players operating in the Psoriatic Arthritis (PsA) Market are Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Cadila Pharmaceuticals (India), Eli Lilly and Company (U.S.), LEO Pharma A/S (Denmark), Cipla Inc. (U.S.), Aurobindo Pharma (India), Lupin (India), Sumitomo Corporation (Japan).
The major countries covered in the Psoriatic Arthritis (PsA) Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.